MRKR
Marker Therapeutics Inc
Halal Rating :
Last Price
$2.51
Last updated:
Market Cap
-
7D Change
-8.23%
1 Year Change
-44.96%
Company Overview
Industries
Exchange
Next Earnings Date
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The company's core technology focuses on multi-tumor-associated antigen (MultiTAA) specific T cells for targeted cancer treatments.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1.93m | $4.33m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $1.17m | $3.48m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $1.24m | $3.79m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Marker Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.